1. Home
  2. TBLA vs MLYS Comparison

TBLA vs MLYS Comparison

Compare TBLA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBLA
  • MLYS
  • Stock Information
  • Founded
  • TBLA 2007
  • MLYS 2019
  • Country
  • TBLA United States
  • MLYS United States
  • Employees
  • TBLA N/A
  • MLYS N/A
  • Industry
  • TBLA Computer Software: Programming Data Processing
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TBLA Technology
  • MLYS Health Care
  • Exchange
  • TBLA Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • TBLA 1.2B
  • MLYS 1.0B
  • IPO Year
  • TBLA N/A
  • MLYS 2023
  • Fundamental
  • Price
  • TBLA $3.46
  • MLYS $15.96
  • Analyst Decision
  • TBLA Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • TBLA 4
  • MLYS 3
  • Target Price
  • TBLA $4.33
  • MLYS $33.00
  • AVG Volume (30 Days)
  • TBLA 2.0M
  • MLYS 886.1K
  • Earning Date
  • TBLA 05-07-2025
  • MLYS 05-12-2025
  • Dividend Yield
  • TBLA N/A
  • MLYS N/A
  • EPS Growth
  • TBLA N/A
  • MLYS N/A
  • EPS
  • TBLA 0.04
  • MLYS N/A
  • Revenue
  • TBLA $1,779,705,000.00
  • MLYS N/A
  • Revenue This Year
  • TBLA $7.69
  • MLYS N/A
  • Revenue Next Year
  • TBLA $6.15
  • MLYS N/A
  • P/E Ratio
  • TBLA $86.83
  • MLYS N/A
  • Revenue Growth
  • TBLA 16.63
  • MLYS N/A
  • 52 Week Low
  • TBLA $2.50
  • MLYS $8.24
  • 52 Week High
  • TBLA $4.30
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • TBLA 65.74
  • MLYS 58.61
  • Support Level
  • TBLA $3.34
  • MLYS $15.04
  • Resistance Level
  • TBLA $3.50
  • MLYS $16.77
  • Average True Range (ATR)
  • TBLA 0.15
  • MLYS 1.10
  • MACD
  • TBLA 0.01
  • MLYS 0.08
  • Stochastic Oscillator
  • TBLA 93.22
  • MLYS 70.18

About TBLA Taboola.com Ltd.

Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, Germany, France, Rest of the world whilst it generates the majority of its revenue from the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: